TIAA CREF Investment Management LLC lowered its position in Inovalon (NASDAQ:INOV) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 176,365 shares of the technology company’s stock after selling 9,707 shares during the quarter. TIAA CREF Investment Management LLC’s holdings in Inovalon were worth $2,645,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its holdings in Inovalon by 5.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 75,204 shares of the technology company’s stock valued at $1,282,000 after buying an additional 3,831 shares during the last quarter. Geode Capital Management LLC grew its holdings in Inovalon by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 587,103 shares of the technology company’s stock valued at $8,806,000 after buying an additional 8,463 shares during the last quarter. FNY Managed Accounts LLC acquired a new stake in Inovalon during the 4th quarter valued at $150,000. Creative Planning acquired a new stake in Inovalon during the 4th quarter valued at $152,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in Inovalon by 3.6% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 317,267 shares of the technology company’s stock valued at $4,760,000 after buying an additional 11,062 shares during the last quarter. Institutional investors and hedge funds own 27.29% of the company’s stock.

Shares of NASDAQ:INOV opened at $10.75 on Friday. The firm has a market cap of $1,545.10, a price-to-earnings ratio of 46.74, a P/E/G ratio of 3.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.82 and a current ratio of 4.82. Inovalon has a one year low of $10.10 and a one year high of $17.80.

Inovalon (NASDAQ:INOV) last posted its quarterly earnings data on Tuesday, February 20th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). Inovalon had a return on equity of 4.79% and a net margin of 7.51%. The business had revenue of $114.60 million for the quarter, compared to analyst estimates of $116.83 million. During the same quarter last year, the business earned $0.05 EPS. Inovalon’s revenue for the quarter was up 19.3% compared to the same quarter last year. equities research analysts forecast that Inovalon will post 0.25 earnings per share for the current year.

A number of equities research analysts have commented on the company. Zacks Investment Research cut Inovalon from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub upgraded Inovalon from a “strong sell” rating to a “sell” rating in a report on Tuesday. TheStreet upgraded Inovalon from a “d+” rating to a “c” rating in a report on Thursday, March 15th. ValuEngine cut Inovalon from a “hold” rating to a “sell” rating in a report on Wednesday, March 14th. Finally, Morgan Stanley cut Inovalon from an “equal weight” rating to an “underweight” rating and set a $10.00 target price on the stock. in a report on Wednesday, March 14th. Three research analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. Inovalon presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Inovalon Company Profile

Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.

Want to see what other hedge funds are holding INOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovalon (NASDAQ:INOV).

Institutional Ownership by Quarter for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.